Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635165 | 0.98 | DPP4 (0.46) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL6809814 | 0.98 | DPP4 (0.46) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL6813964 | 0.94 | DPP4 (0.47) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL4635981 | 0.94 | DPP4 (0.47) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL4635175 | 0.94 | DPP4 (0.47) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL4634563 | 0.94 | DPP4 (0.47) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL4634896 | 0.93 | DPP4 (0.48) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL9613104 | 0.93 | DPP4 (0.48) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL4634245 | 0.92 | DPP4 (0.45) | DPP4CHRM2DRD1MAOALMNA | |
| SCHEMBL6809376 | 0.92 | DPP4 (0.44) | DPP4CHRM2DRD1MAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132764-A1 | Antibiotics for the treatment of infections in acidic environments | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132764-A1 | Antibiotics for the treatment of infections in acidic environments | IL17A, OXA1L, NQO2 | DPP4 1735/4885CHRM2 4789/4885DRD1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.